Entrada Therapeutics Inc’s recently made public that its Director PARMAR KUSH unloaded Company’s shares for reported $0.2 million on Jul 09 ’25. In the deal valued at $7.50 per share,27,000 shares were sold. As a result of this transaction, PARMAR KUSH now holds 1,093,313 shares worth roughly $6.37 million.
Then, 5AM Ventures V, L.P. sold 20,065 shares, generating $150,528 in total proceeds. Upon selling the shares at $7.50, the 10% Owner now owns 3,163,066 shares.
Before that, 5AM Ventures V, L.P. sold 6,935 shares. Entrada Therapeutics Inc shares valued at $52,026 were divested by the 10% Owner at a price of $7.50 per share. As a result of the transaction, 5AM Ventures V, L.P. now holds 1,093,313 shares, worth roughly $6.37 million.
ROTH MKM initiated its Entrada Therapeutics Inc [TRDA] rating to a Buy in a research note published on December 06, 2024; the price target was $29. A number of analysts have revised their coverage, including Oppenheimer’s analysts, who began to cover the stock in early January with a ‘”an Outperform”‘ rating. H.C. Wainwright began covering TRDA with “Buy” recommendation on April 03, 2023.
Price Performance Review of TRDA
On Tuesday, Entrada Therapeutics Inc [NASDAQ:TRDA] saw its stock fall -1.52% to $5.83. Over the last five days, the stock has lost -7.31%. Entrada Therapeutics Inc shares have fallen nearly -63.47% since the year began. Nevertheless, the stocks have fallen -66.28% over the past one year.
How much short interest is there in Entrada Therapeutics Inc?
A steep rise in short interest was recorded in Entrada Therapeutics Inc stocks on 2025-07-15, growing by 0.2 million shares to a total of 1.3 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 1.1 million shares. There was a rise of 15.04%, which implies that there is a positive sentiment for the stock.
